4.23
+0.23(+5.75%)
Currency In USD
| Previous Close | 4 |
| Open | 4 |
| Day High | 4.24 |
| Day Low | 3.81 |
| 52-Week High | 4.86 |
| 52-Week Low | 1.27 |
| Volume | 2.39M |
| Average Volume | 1.66M |
| Market Cap | 584.95M |
| PE | -8.81 |
| EPS | -0.48 |
| Moving Average 50 Days | 3.78 |
| Moving Average 200 Days | 2.86 |
| Change | 0.23 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $497.65 as of November 10, 2025 at a share price of $4.23. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $1,036.76 as of November 10, 2025 at a share price of $4.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Nov 04, 2025 2:00 PM GMT
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, inclu
Compass Therapeutics to Participate in Upcoming November Investor Events
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today
Compass Therapeutics to Participate in Upcoming September Investor Events
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today